How do I prescribe and manage mIDH inhibitors in patients with IDH-mutant glioma?

Details

Request a copyRequest a copy
Serval ID
serval:BIB_B51DC96C59A9
Type
Article: article from journal or magazin.
Collection
Publications
Institution
UNIL/CHUV
Title
How do I prescribe and manage mIDH inhibitors in patients with IDH-mutant glioma?
Journal
Neuro-oncology practice
Author(s)
Still MEH, Moor RSF, Ghiaseddin A.P., Leibetseder A., Hottinger A.F., Berghoff A., Leung D.
ISSN
2054-2577 (Print)
ISSN-L
2054-2577
Publication state
Published
Issued date
02/2025
Peer-reviewed
Oui
Volume
12
Number
Suppl 1
Pages
i19-i25
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Abstract
Recent interest has been in using mIDH inhibitors in patients with IDH-mutant gliomas. This review paper summarizes the indications, side effects, recommended dosing, and management for patients on ivosidenib and vorasidenib.
Keywords
IDH inhibitor, glioma, ivosidenib, prescribing, vorasidenib
OAI-PMH
oai:serval.unil.ch:BIB_B51DC96C59A9
DOI
10.1093/nop/npae112
Pubmed
39776526
Web of science
001377098400001
Create date
09/01/2025 16:22
Last modification date
21/01/2025 7:11
Usage data